Prostate Cancer Treatment: Abiraterone and other hormonal therapies being studied
Monday, May 22, 2017
This is an excerpt of a story that appeared in Cancer Therapy Advisor. Read the full article here.
Though the number of available therapies has increased during recent years, men with metastatic castration-resistant prostate cancer (mCRPC) inevitably have disease progression due to acquired resistance to treatment.
“By understanding mechanisms of resistance to our current therapies, we will be better able to develop new strategies to combat resistance and improve quantity and quality of life,” Scott Tagawa, MD, MS, told Cancer Therapy Advisor. “This may come from new drugs, new combinations of existing drugs, or better biomarkers.”
CRPC develops when prostate cancer progresses despite castrate-levels of testosterone, which may be explained by continued androgen receptor (AR) signaling driving tumor growth.
There are multiple mechanisms that can promote AR signaling, including AR splice variants, AR amplification or overexpression, AR stabilization, overexpressed transcription factors, AR mutations, and alternate signaling pathways.
None of these mechanisms are possible, however, without continued androgen production, such as by intratumoral steroidogenesis.
“We know that men with undetectable serum levels of testosterone can have cancer growth and abiraterone can be effective in men with progressive cancer despite no detectable serum testosterone,” said Dr Tagawa, suggesting that another source of testosterone is promoting tumor growth.
Studies indicate that even after androgen-deprivation therapy (ADT) intratumoral androgen synthesis can reactivate the AR. Testosterone and dihydrotestosterone (DHT) are synthesized from weak androgens produced by the adrenal glands, as well as de novo synthesis from cholesterol, within the tumor.
This is consistent with studies demonstrating higher levels of intratumoral androgens among men with mCRPC compared with men with primary prostate cancer. Higher intratumoral expression of CYP17A1, AKR1C3, and 3ßHSD — enzymes involved in androgen synthesis — is also associated with intratumoral androgen levels.
Abiraterone is a CYP17 inhibitor that reduces circulating and intratumoral androgens, “decreasing the available ligand for the AR, which is testosterone or DHT. This comes from the testicles, as well as other sources such as the adrenal glands and tumors themselves,” said Dr Tagawa.
Increasing intratumoral androgen production could, however, overcome the therapeutic concentration of abiraterone, particularly if androgen synthesis occurred by a mechanism other than CYP17.
More studies are needed to further define the role of intratumoral androgen production and mCRPC resistance to hormonal therapies, and to determine if inhibitors of other steroidogenesis enzymes can be synergistic with abiraterone.
A challenge in studying intratumoral androgen production is that “there is no current standard way to detect androgen production by individual tumor cells if it is not enough to detect in the blood. It may be possible through molecular imaging if there is sufficient signal, but this is not standard,” Dr Tagawa commented.
“The best studies at this point are still tissue studies,” Dr Tagawa said of intratumoral androgen production, “but additional molecular imaging techniques could be a step forward.”